BIIB - Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings

2024-04-30 13:40:00 ET

Summary

• Biogen Inc. has faced challenges lately, including declining sales of its multiple sclerosis drugs and setbacks in developing an Alzheimer's drug.
• The company's stock price has fluctuated, reaching highs of over $350 per share but falling to lows of under $200 per share recently.
• Biogen's new CEO, Chris Viehbacher, has implemented a cost savings program to address profitability issues and focus on operational execution.
• Alzheimer's drug Leqembi has overcome controversy to win full approval and is growing revenues - this trend can help support growth in Biogen's share price - and perhaps a return to >$300 per share.

Investment Overview: Brief History Of Biogen Since 2019 - Declining MS Sales, Alzheimer's Struggles

Biogen Inc. ( BIIB ) - the Cambridge, Massachusetts headquartered, neurological and neurodegenerative disease treatment specialist - has had a tumultuous few years, characterized by moments of extreme optimism, followed by lengthy periods of disappointment....

For further details see: